Tempus AI Dominates Alternate Health in Key Metrics

A financial comparison of Tempus AI (NASDAQ:TEM) and Alternate Health (OTCMKTS:AHGIF) shows Tempus AI outperforming on 6 of 9 measured factors. Analysts give Tempus AI a consensus buy-leaning rating with a target price of $75.92, representing a potential 76.81% upside. Despite posting a net loss of $245 million and negative margins, Tempus AI holds $1.27 billion in gross revenue and 24.2% institutional ownership. Alternate Health, a Canadian cannabis software firm, lacks comparable financial data, making direct valuation metrics impossible to assess.